Supplementary Table S3 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation
Timothy A. Lin,Zachary R. McCaw,Alex Koong,Christine Lin,Joseph Abi Jaoude,Roshal Patel,Ramez Kouzy,Molly B. El Alam,Alexander D. Sherry,Sonal S. Noticewala,Clifton D. Fuller,Charles R. Thomas,Ryan Sun,J. Jack Lee,Ruitao Lin,Ying Yuan,Yu Shyr,Tomer Meirson,Ethan B. Ludmir
DOI: https://doi.org/10.1158/1078-0432.27231412
2024-01-01
Abstract:Table S3: List of 341 trials included in the overall analysis. ADT, androgen deprivation therapy; mFOLFOX, folinic acid, fluorouracil, and oxaliplatin; FOLFIRI, folinic acid, fluorouracil, irinotecan; GM-CSF, granulocyte-macrophage colony-stimulating factor; R-DHAP; rituximab, dexamethasone, cytarabine, cisplatin; O-DHAP; ofatumumab, dexamethasone, cytarabine, cisplatin; EDP, etoposide doxorubicin cisplatin; G-CHOP, obintuzumab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisone; RCHOP, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisone; VR-CAP, rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib; AC, Adriamycin with cyclophosphamide; T, paclitaxel; XT, capecitabine plus paclitaxel; GIST, gastrointestinal stromal tumor; IFN, interferon; 5FU, 5-fluorouracil; FA, folinic acid; recMAGE-A3, recombinant MAGE A-3; NGR-Htnf, NGR–human tumor necrosis factor; TACE, trans-arterial chemoembolization; T-DM1, Trastuzumab emtansine; Mf, mitomycin-C and fluoropyrimidine; iceMFP, intraperitoneal cisplatin (100 mg), intravenous mitomycin-C (15 mg/m(2)) on postoperative day 1, followed by oral doxifluridine for 12 months, and six monthly intravenous cisplatin (60 mg/m(2); RFA, radiofrequency ablation.